Parthenon Therapeutics

Biotechnology, Life Science, Therapeutics
Founded in 1/1/19
Cambridge, Massachusetts, United States
http://www.parthenontx.com/
For Profit

About Parthenon Therapeutics

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 65000000 USD
  • Last Funding: 65000000 USD (Series A)
  • Funding Status: Early Stage Venture

Technology Stack

Parthenon Therapeutics actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Life Science, Therapeutics

Headquarters: Cambridge, Massachusetts, United States

Employees